Group 1 - Core viewpoint: Meinuo Pharma (603538) announced that its wholly-owned subsidiary, Meinuo Tiankang, is participating in the national centralized procurement bidding, with ten products including Perindopril tert-butylamine tablets expected to be selected, covering cardiovascular and anti-infection fields [1] - Expected sales: The total sales for the first three quarters of 2025 are projected to be 71.75 million yuan, accounting for 6.4% of the company's revenue during the same period [1] - Implementation timeline: The selection results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028 [1] Group 2 - Recent stock performance: Over the past seven trading days (from February 6 to February 13, 2026), Meinuo's stock price fluctuated within a range of 4.90%, with the latest closing price at 21.18 yuan, reflecting a slight increase of 0.76% compared to February 6 [2] - Capital flow: On February 13, the net outflow of main funds was 2.2299 million yuan, while retail funds saw a net inflow; the turnover rate remained stable between 1% and 3% [2] - Market comparison: The overall performance of Meinuo was slightly better than the chemical pharmaceutical sector, which saw a decline of 0.97%, but weaker than the overall market index [2]

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products including Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets expected to be selected for this procurement [1]. Group 1: Proposed Selected Products - The ten proposed selected products are expected to generate a total sales revenue of 71.75 million yuan in the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1]. - The number of proposed selected products represents 40% of the total number of formulations in the company's formulation segment [1]. Group 2: Impact on the Company - The results of the procurement are expected to be implemented by the end of March 2026, with medical institutions prioritizing the use of the selected drugs during the procurement cycle [1]. - The procurement cycle for the selected drugs will last until December 31, 2028, starting from the actual execution date of the selection results [1].

Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] - The procurement is part of the continuation of the national centralized procurement for drugs from batches 1-8, with results expected to be implemented by the end of March 2026 [1] Group 2: Financial Impact - The total sales for the ten selected products are projected to be 71.75 million yuan for the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1] - The number of selected products represents 40% of the total products in the formulation segment of the company [1] Group 3: Procurement Cycle - The procurement cycle for the selected drugs will run from the actual execution date of the selection results until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle and ensure the completion of the agreed procurement volume [1]

Core Viewpoint - Meinuohua's subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., is participating in the national organized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The company is involved in the bidding for the continuation of procurement for drugs that are part of the first to eighth batches of the national organized procurement agreements that have expired [1] - The expected selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] Group 2: Procurement Timeline - The results of the procurement selection are anticipated to be implemented by the end of March 2026 [1] - The procurement cycle for the selected drugs will last from the actual execution date of the selection results until December 31, 2028 [1] Group 3: Procurement Prioritization - During the procurement cycle, medical institutions will prioritize the use of the drugs selected in this continuation procurement and ensure the completion of the agreed procurement volume [1]

Core Insights - Meihua's total revenue for 2024 reached 1.373 billion yuan, marking a year-on-year increase of 12.85%, while net profit attributable to shareholders surged by 476.64% to 67 million yuan [1] - The company's CDMO business faced a significant decline, with revenue dropping by 39.30%, raising concerns about future profitability [5] Group 1: Business Performance - The formulation business exhibited strong growth, with revenue increasing by 83.52%, driven by the approval of multiple products and successful bids in various provinces [4] - The raw material business showed a recovery with a revenue growth of 6.10%, supported by the significant increase in the Sitagliptin product line, despite challenges from geopolitical tensions and rising raw material costs [4] Group 2: CDMO Business Challenges - The CDMO business experienced a notable revenue decline of 39.30%, influenced by factors such as investment disruptions, high base effects from COVID-19, price wars, and geopolitical issues [5] - The low performance of the CDMO segment not only affected the overall revenue structure but also posed challenges to future profitability, necessitating a reevaluation of business strategies [5] Group 3: R&D and Innovation - Meihua increased its R&D investment to 131 million yuan, accounting for 9.56% of total revenue, focusing on innovative areas such as GLP-1 delivery systems and mRNA drug delivery systems [6] - The company is actively exploring emerging markets, developing products in weight loss and anti-aging, which could provide new growth opportunities in the future [6]